Biogen Idec Inc: All Recent News

• All recent news
• Earnings news

Final Glance: Biotechnology companies 11/24/2009

NEW YORK (AP) - Shares of some top biotechnology companies were mixed at the close of trading:... Associated Press

Early Glance: Biotechnology companies 11/24/2009

NEW YORK (AP) - Shares of some top biotechnology companies are mixed at 10 a.m.:... Associated Press

($) Fitz Bits: Wait for a Retest in Ford 11/23/2009

I'd be a buyer if the stock holds up at $8. At TheStreet.com

A Big Upgrade for Allos Therapeutics 11/23/2009

This bullish call comes from more than just one analyst. At Motley Fool

A Big Upgrade for Allos Therapeutics 11/23/2009

This bullish call comes from more than just one analyst. Motley Fool

UPDATE 2-HealthCor slams Biogen CEO for outsize pay package 11/20/2009

... At Thomson Reuters

This Stock Is a Train Wreck 11/19/2009

Genzyme's string of missteps has investors nervous. At Motley Fool

Genentech, Biogen get FDA request on Rituxan 11/18/2009

NEW YORK (AP) - Genentech Inc. and partner Biogen Idec Inc. said Wednesday the Food and Drug Administration is withholding a decision to expand approval of Rituxan as a leukemia treatment, pending further discussion. Associated Press

Market Report -- In Play (BIIB) 11/18/2009

Biogen Idec and Genenech receive a complete response from the FDA for Rituxan for chronic lymphocytic leukemia Genentech, a wholly-owned member of the Roche, and BIIB announced that the FDA issued a... Briefing.com

Genzyme's Termeer: Worst Biotech CEO of '09 11/17/2009

Genzyme CEO Henri Termeer is Adam Feuerstein's Worst Biotech CEO of the Year for 2009. At TheStreet.com

Abbott: Brave or Stupid? 11/13/2009

The company makes a deal that could pay off big, but could flame out instead. At Motley Fool

When Rival Drug Makers Compare Notes On Safety Problems 11/11/2009

... At Wall Street Journal

ETF Picks: Consider This Diversified Partial Portfolio 11/10/2009

Editor's note: The following is an edited version of the first edition of the Grail ETF & Equity Investor newsletter by Ron Coby & Denny Lamson using their proprietary Lamson Grail Timing Indicator. This premium newsletter was just launched by Minyanville on Monday. Learn more or sign up for a FREE 14 day trial to receive future issues.We're very excited to team with Minyanville on this newsletter and pledge to deliver our most timely ETF and market calls to you. In this launch phase of our program we find ourselves in a very interesting time. It's a period of ... At Minyanville

Zacks Industry Outlook Highlights: Alcon, Novartis, Gilead... 11/10/2009

Zacks.com releases the latest Industry Outlook. Today, Zacks Equity Research discusses the Big Pharma & Biotech Industry, including Alcon (NYSE: ACL), Novartis (NYSE: NVS), Gilead Sciences... Business Wire

CORRECTING and REPLACING Biogen Idec to Present at the 2009... 11/10/2009

First graph, first sentence of release dated November 9, 2009, should read: ...Friday, November 13, 2009 at 8:30 a.m. MST, 10:30 a.m. EST. (sted ...Friday, November 13, 2009 at 8:30 a.m. MST, 6:30... Business Wire

More News

Market Report

News by Symbol

Today's Investing Articles

Breaking News

News by Topic

News by Industry

MSNBC News

MSN Money

Search MSN Money

Message Boards

Site Status